TuHURA Secures U.S. Patent for DOR ADC Platform, Bolstering Pipeline
HURA has more than doubled off its 52-week low of $0.41.
Summary
TuHURA received a U.S. patent covering its delta opioid receptor (DOR) antibody drug conjugate (ADC) technology. This is a new, company-specific intellectual property milestone that strengthens the company's proprietary position in a novel oncology approach. The patent grant follows recent FDA clearance for a Phase 1b study of TBS-2025 and comes amid a tight cash position, with $1.0 million in cash as of June 30 and reliance on a $50 million credit facility. The patent could enhance the value of the DOR ADC program and support future partnering or financing discussions. No financial terms or licensing agreements were disclosed.
At the time of this announcement, HURA was trading at $1.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $121.7M. The 52-week trading range was $0.41 to $3.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.